Axsome Therapeutics (AXSM) announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 for the management of fibromyalgia. FORWARD is a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial in patients with fibromyalgia consisting of an open-label AXS-14 treatment period and a randomized, double-blind treatment period.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $209 from $157 at Baird
- Axsome Therapeutics price target raised to $193 from $157 at Wells Fargo
- Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth
- Buy Rating on Axsome Therapeutics Backed by Strong Auvelity and Sunosi Outperformance Despite Slower Symbravo Ramp
- Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth